beta-adrenergic receptor Agonists
19 drugsAbout beta-adrenergic receptor
The beta-adrenergic receptor (β-adrenergic receptor) is a GPCR mediating catecholamine effects, influencing heart rate, bronchodilation, and metabolism.
Human genetics strongly support beta-adrenergic receptor targeting, with hypertension (score 0.89), essential hypertension (0.83), and cardiovascular disease (0.79) associations. Loss-of-function variants are protective, suggesting inhibition is beneficial.
Nineteen small molecule drugs target beta-adrenergic receptors, including ADRENALIN, COREG, and NEFFY, spanning 'other' indications (15), cardiovascular (2), and ophthalmology (2).
Strategic Insights
ℹ️ How we calculate- White space opportunity in HIV Infections with only 4 trials.
beta-adrenergic receptor Genetic Evidence Strong
Strong genetic evidence supports ADRB1's role in hypertension and cardiovascular disease.
High genetic scores suggest clinical trials targeting hypertension have increased likelihood of success.
💡 Why inhibition?
- • Loss-of-function variants reduce disease risk (OR < 1)
- • 100% directional consistency across 3 traits
- • Strong signal in cardiovascular disease, phenotype pathways
Cross-Disease Effects
Trade-off: LowDirection of Effect
100% alignedEvidence Across Diseases
9 totalGWAS and other genetic studies link ADRB1 to 9 diseases.
Inhibiting this target may be therapeutic
Inhibiting this target may be therapeutic
🔗 Colocalization Evidence 20 strong
max H4: 1.00eQTL/pQTL signals for ADRB1 colocalize with these GWAS traits, providing causal evidence that gene expression changes drive disease risk.
Understanding these scores
Association Score (0-1): Combines all evidence types (genetic, literature, drugs, animal models). Higher = more evidence linking target to disease. This is a ranking heuristic, not a confidence score.
L2G Score: Open Targets uses a machine learning model (Locus-to-Gene) to predict which gene is causal at each GWAS locus. L2G=0.5 means ~50% probability of being the causal gene. Only associations with L2G > 0.05 are included.
Odds Ratio (OR): From gene burden studies (UK Biobank, AstraZeneca PheWAS). Measures how loss-of-function variants affect disease risk. OR<1 = protective (inhibiting target may help), OR>1 = risk (losing function causes disease).
Beta (β): Effect size for continuous traits. β<0 = protective, β>0 = risk.
Clinical Translation (~1.8x): Based on Nelson et al. 2015: drug targets with genetic evidence have ~2x higher success rates in clinical trials. We estimate: Strong support (score ≥0.7) → ~1.8x, Moderate (0.3-0.7) → ~1.3x, Weak → baseline.
Colocalization (H4): Tests whether a GWAS signal and an eQTL/pQTL signal share the same causal variant. H4 is the posterior probability that both traits are associated AND share a causal variant. H4 > 0.8 = strong evidence that gene expression/protein levels drive disease risk. This links genetic variation → gene expression → disease, supporting the target-disease connection.
Top beta-adrenergic receptor Drugs
Sixteen companies have approved beta-adrenergic receptor drugs, including GLENMARK PHARMS LTD and ADAMIS PHARMS CORP.
A fragmented market suggests moderate entry barriers, but established players have an advantage.
| Drug | Company | Approved | Indications |
|---|---|---|---|
| BRIMONIDINE TARTRATE AND TIMOLOL MALEATE | Apotex | 2022 | 2 |
| EPIPEN | Viatris | 1987 | 2 |
| EPIPEN JR. | Viatris | 1987 | 2 |
| NEFFY | ARS PHARMS OPERATION | 2024 | 2 |
| ADRENACLICK | IMPAX LABS | 2003 | 2 |
| SYMJEPI | ADAMIS PHARMS CORP | 2017 | 2 |
| COMBIGAN | AbbVie | 2007 | 2 |
| XYLOCAINE W/ EPINEPHRINE | AstraZeneca | 1948 | 2 |
| EPINEPHRINE (AUTOINJECTOR) | Teva | 2018 | 2 |
| NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE | Baxter | 2021 | 1 |
| NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE | Baxter | 2021 | 1 |
| NOREPINEPHRINE BITARTRATE | RISING | 2003 | 1 |
| AKOVAZ | EXELA PHARMA | 2016 | 1 |
| LEVOPHED | Pfizer | 1950 | 1 |
| CORPHEDRA | PH HEALTH | 2017 | 1 |
| EMERPHED | NEXUS | 2020 | 1 |
beta-adrenergic receptor Drug Modality Landscape
Modalities
Routes of Administration
beta-adrenergic receptor is amenable to small molecule drugs, with oral options available for convenient dosing.
Exploring alternative modalities like antibodies or peptides may offer differentiation opportunities.
beta-adrenergic receptor Clinical Trials 570 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 75 | 50 | 14 | 9 | 78% |
| Phase 2 | 132 | 80 | 22 | 29 | 78% |
| Phase 3 | 107 | 78 | 10 | 17 | 89% |
| Phase 4 | 256 | 178 | 30 | 44 | 86% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
beta-adrenergic receptor Drug Approval Timeline (1950 - 2024)
Approvals span 77 years from 1948 (XYLOCAINE W/ EPINEPHRINE) to 2024 (NEFFY).
Consistent approvals indicate sustained interest, but recent approvals may signal renewed focus.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 16 companies competing
- • Market share by company
Full Drug Portfolio
- • All 19 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 19-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 7 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 494 clinical trials targeting beta-adrenergic receptor.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities